Powder: -20°C for 3 years | In solvent: -80°C for 1 year
T-900607是一种新型微管蛋白活性剂,通过独特的作用机制破坏微管聚合。t-900607具有心脏毒性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,300 | 现货 | ||
5 mg | ¥ 2,900 | 现货 | ||
10 mg | ¥ 4,290 | 现货 | ||
25 mg | ¥ 6,850 | 现货 | ||
50 mg | ¥ 9,270 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
500 mg | ¥ 24,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,120 | 现货 |
产品描述 | T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic. |
靶点活性 | HeLa cells:< 5 μM, MCF-7/ADR cells:< 5 μM |
体外活性 | t-900607 (compound 5 or VI) showed total growth inhibition for HeLa and MCF-7/ADR cells at<5 μM.[2] |
体内活性 | t-900607 (15 to 270 mg/m; administered intravenously; advanced and/or metastatic solid malignancies patients; over 30 minutes every 21 days) no DLTs were seen until 270 mg/m, the sixth dose level. The dose was decreased to 180 mg/m with increased cardiac monitoring and at this dose 3/4 of patients experienced cardiac toxicity. The study was reopened at 130 mg/m of 6 enrolled patients, 1 had grade 3 drug-related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported on 7/20. The recommended phase II dose for t-900607 is 130 mg/m given as an intravenous infusion over 60 minutes on a 21-day cycle. Cardiac toxicity was seen with this schedule.[1] |
分子量 | 411.3 |
分子式 | C14H10F5N3O4S |
CAS No. | 261944-52-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.11 mg/mL (10 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4313 mL | 12.1566 mL | 24.3132 mL | 60.7829 mL |
5 mM | 0.4863 mL | 2.4313 mL | 4.8626 mL | 12.1566 mL | |
10 mM | 0.2431 mL | 1.2157 mL | 2.4313 mL | 6.0783 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
T-900607 261944-52-9 Cytoskeletal Signaling Microtubule Associated Inhibitor inhibitor inhibit